Why has the 4D Medical share price popped 7% in a month?

4DMedical unveiled its XV Scanner, the world's first dedicated lung scanner, at Prince of Wales Hospital in Sydney in March.

| More on:
Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The 4DMedical share price is volatile on Tuesday morning 
  • The company's net loss after tax increased 15% from the prior year 
  • It also ended the year with a strong cash balance and no debt 

The 4DMedical Ltd (ASX: 4DX) share price is seeing some significant swings today, from gains of 2% to losses of more than 2% in morning trading.

4DMedical shares closed yesterday at 65 cents each and are currently at 63 cents a share, down 2.3% for the day, but still up 7% for the month.

This comes following Friday's release of the respiratory imaging technology company's full-year results for the 12 months ending 30 June (FY22). The 4DMedical share price closed up 4.7% on the day.

Here are the highlights:

4DMedical share price in the spotlight amid FY22 results

  • Total income of $13.4 million, up 132% from FY21
  • Revenues from ordinary activities of $1.1 million, increased 386% year on year
  • Net loss after tax of $24.6 million, a 15% increase from FY21
  • Cash reserve of $51.1 million and no debt as at 30 June 2022

What else happened during the year?

While income and revenues increased, so did the company's operating expenses, which rose 51% year on year to $37 million. 4DMedical said the increase was largely due to more spending on research and development and in support of commercialisation.

Other milestones during the year included the company signing a nationwide contract with I-MED, Australia's largest outsourced radiology provider.

The ASX medical tech share also progressed in the United States, where scanning commenced at its first US clinical pilot at Providence St. Joseph Hospital in California.

And in an FY22 highlight, 4DMedical unveiled its XV Scanner, the world's first dedicated lung scanner, at Prince of Wales Hospital in Sydney on 17 March. The scanner was delivered with the help of the Medical Research Future Fund (MRFF), with a $28.9 million contribution from the Australian government.

What did management say?

Commenting on the results, 4DMedical CEO Andreas Fouras said:

From a financial performance perspective, we have grown Software-as-a-Service (SaaS) revenue as well as hardware sales. While these gains have been from a low base, they clearly demonstrate that the Company is now very much in its commercialisation phase…

The 4DMedical team has been busy adding to our catalogue of pilot and clinical trial results, which are rapidly adding to the body of evidence that scans generated via 4DMedical's XV LVAS technology are a superior way of examining patients.

What's next?

4DMedical said it "has a significant cash runway of at least six quarters". The company has a cash balance of $51.1 million and has yet to receive the $15 million in MRFF funds.

Looking ahead, Fouras added:

Subsequent to the end of the reporting period, the US signed into law a broad expansion of healthcare benefits for millions of veterans suffering from respiratory diseases acquired while serving their country. This will include increased testing to identify these disorders, providing a significant opportunity for 4DMedical.

4DMedical share price snapshot

Despite the strong past month, the 4DMedical share price has struggled this year, down 53% since the opening bell on 4 January. By comparison, the All Ordinaries Index (ASX: XAO) is down 8% year-to-date.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

Hand of a woman carrying a bag of money, representing the concept of saving money or earning dividends.
Earnings Results

Which ASX shares delivered the biggest profit jumps of the earnings season?

These companies revealed at least a 70% profit boost in their latest earnings reports.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Earnings Results

Why this ASX 300 share is leaping 14% despite being branded a 'sell'

Falling profits are putting investors off the fund manager.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Technology Shares

Life360 share price rockets 24% after smashing FY23 earnings expectations

This tech stock delivered a very strong result this morning. How strong was it?

Read more »

a man in a shirt and tie holds his chin in thoughtful contemplation and looks skywards as if thinking about something while a graphic of a road with many ups and downs unfurls behind him.
Earnings Results

What's with the Neuren Pharmaceuticals share price today?

The full market reaction to the Daybue developer's FY23 earnings report won't be seen until tomorrow.

Read more »

Two workers at an oil rig discuss operations.
Earnings Results

2 ASX energy shares going gangbusters on today's earnings results

The ASX energy shares are drawing investor interest today after releasing their half-year earnings results.

Read more »

Man pointing at a blue rising share price graph.
Earnings Results

This ASX 300 stock just jumped 12%! Here's why

The ASX 300 stock is impressing investors with its half-year earnings results.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Earnings Results

Mesoblast share price tumbles on US$32.5m half-year loss

This biotech continues to burn cash.

Read more »

Man and woman sitting at casino table playing poker
Earnings Results

Star Entertainment share price jumps 5% on strengthening outlook

ASX 200 investors are bidding up the Star Entertainment share price on Thursday.

Read more »